Kezar Life Sciences, Inc. (KZR) financial statements (2022 and earlier)

Company profile

Business Address 4000 SHORELINE COURT, SUITE 300
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments208,355140,44778,206107,432
Cash and cash equivalents62,88221,22814,95124,182
Short-term investments145,473119,21963,25583,250
Prepaid expense2,5702,7331,8781,884
Other current assets7291,6311,048489
Total current assets:211,654144,81181,132109,805
Noncurrent Assets
Operating lease, right-of-use asset2,7143,3143,817
Property, plant and equipment3,2833,4354,2824,595
Other noncurrent assets282282282282
Total noncurrent assets:6,2797,0318,3814,877
TOTAL ASSETS:217,933151,84289,513114,682
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,0135,3795,0412,871
Accounts payable2,0282,358823193
Accrued liabilities4,9853,0214,2182,678
Debt  900 
Deferred rent credit   354
Other liabilities 2162112
Other undisclosed current liabilities1,1991,042  
Total current liabilities:8,2126,4426,0033,337
Noncurrent Liabilities
Long-term debt and lease obligation12,8454,4225,464 
Long-term debt, excluding current maturities9,622   
Operating lease, liability3,2234,4225,464
Liabilities, other than long-term debt   2,548
Deferred rent credit   2,548
Other undisclosed noncurrent liabilities(3,223)(4,422)  
Total noncurrent liabilities:12,8454,4225,4642,548
Total liabilities:21,05710,86411,4675,885
Stockholders' equity
Stockholders' equity attributable to parent196,876140,97878,046108,797
Common stock56461919
Additional paid in capital377,765267,093162,505158,176
Accumulated other comprehensive loss(291)(137)(196)(203)
Accumulated deficit(180,654)(126,024)(84,282)(49,195)
Total stockholders' equity:196,876140,97878,046108,797
TOTAL LIABILITIES AND EQUITY:217,933151,84289,513114,682

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Operating expenses(54,659)(42,950)(37,342)(24,726)
Operating loss:(54,659)(42,950)(37,342)(24,726)
Interest and debt expense(159)   
Loss before gain (loss) on sale of properties:(54,818)(42,950)(37,342)(24,726)
Other undisclosed net income1881,2082,2551,559
Net loss available to common stockholders, diluted:(54,630)(41,742)(35,087)(23,167)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(54,630)(41,742)(35,087)(23,167)
Comprehensive loss:(54,630)(41,742)(35,087)(23,167)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(154)597(92)
Comprehensive loss, net of tax, attributable to parent:(54,784)(41,683)(35,080)(23,259)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: